Global Economic Slowdown and Capital Markets: The IMF's downgraded global growth forecasts and threats to global growth from the Middle East conflict could create a challenging economic environment, potentially impacting Alpha Cognition's ability to raise capital for R&D and commercialization of products like ZUNVEYL.

Healthcare Sector Funding and Regulatory Environment: As a biopharmaceutical company, Alpha Cognition is sensitive to trends in healthcare spending, public/private funding for research, and regulatory changes (e.g., FDA approvals). A volatile economic climate could indirectly influence these factors.

Inflationary Pressures and Operating Costs: Rising oil prices due to the Middle East conflict could lead to higher inflation, increasing Alpha Cognition's operating costs for manufacturing, transportation, and labor, thereby impacting its profitability and cash burn rate.